FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB

The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet